Adenovirus E1A fragments for use in anti-cancer therapies
US8716014B2 · kind B2 · utility
0Cited by
1References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 18, 2012 |
| Grant date | May 6, 2014 |
| Priority date | — |
| Expiry date | Jul 18, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/10332
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to an improved cancer therapy comprising co-administration with the E1A 1-80 transcription-repression domain activity. In addition, E1A 1-80 can act as a monotherapy against cancers that express elevated HER2/Neu or in combination with anti-HER2/Neu, chemo- or radiotherapeutic treatments.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.